Pharmacology, Clinical Clinical Trial
Official title:
An Open Label Crossover Pharmacokinetic Trial of Aspirin Dry Powder Versus Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adult Subjects
To evaluate the bioavailability of a single oral dose of the Acetylsalicylic Acid containing dry powder 500 mg in comparison to the bioavailability of a single oral dose of aspirin tablets and aspirin effervescent tablets in healthy adults.
n/a
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00941057 -
Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium
|
Phase 1 | |
Completed |
NCT01707407 -
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
|
Phase 1 | |
Terminated |
NCT04320771 -
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 | |
Completed |
NCT00855660 -
Effect of Riociguat on Bone Metabolism
|
Phase 1 | |
Completed |
NCT03929861 -
Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations
|
Phase 1 | |
Completed |
NCT01489488 -
Relative Bioavailability and Food Effect Study
|
Phase 1 | |
Completed |
NCT01044524 -
Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion
|
Phase 1 | |
Terminated |
NCT04322253 -
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 |